Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $194.8 million.

  • Allogene Therapeutics' Shares Outstanding (Diluted Average) rose 6.14% to $222.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.0 million, marking a year-over-year increase of 6.14%. This contributed to the annual value of $194.8 million for FY2024, which is 24.14% up from last year.
  • Per Allogene Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $194.8 million for FY2024, which was up 24.14% from $156.9 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $194.8 million in FY2024 and a low of $120.4 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $156.9 million (2023), whereas its average is $165.0 million.
  • Data for Allogene Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 24.14% (in 2024) over the last 5 years.
  • Allogene Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $120.4 million in 2020, then increased by 12.84% to $135.8 million in 2021, then climbed by 5.39% to $143.1 million in 2022, then grew by 9.63% to $156.9 million in 2023, then rose by 24.14% to $194.8 million in 2024.